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Recent studies indicate that abnormalities of the alpha-chain of the interleukin-3 receptor (IL-3RA or CD123) are
frequently observed in some leukemic disorders and may contribute to the proliferative advantage of leukemic cells.
This review analyzes the studies indicating that CD123 is overexpressed in various hematologic malignancies,
including a part of acute myeloid and B-lymphoid leukemias, blastic plasmocytoid dendritic neoplasms (BPDCN) and
hairy cell leukemia.
Given the low/absent CD123 expression on normal hematopoietic stem cells, attempts have been made at preclinical
first, and then at clinical level to target this receptor. Since the IL-3R is a membrane receptor there are two relatively
simple means to target this molecule, either using its natural ligand or neutralizing monoclonal antibodies. Recent
reports using a fusion molecule composed by human IL-3 coupled to a truncated diphteria toxin have shown
promising antitumor activity in BPDCN and AML patients.Introduction
The Interleukin (IL)-3, IL-5 and Granulocyte-Macrophage
Colony Stimulating Factor (GM-CSF) Receptor, form a
subfamily of membrane receptors, known as the Beta
Common (βc) family of cytokines because these three re-
ceptors share the common signaling subunit βc . Each of
these three receptors is a heterodimer, composed by a
cytokine-specific α subunit and a common βc subunit, en-
abling high-affinity binding and cell signaling. These three
cytokines play multiple biological functions, being involved
in the control of normal and malignant hemopoiesis, native
and adaptive immunity, and inflammatory response.
The structure, the function and main biological actvities
of these three cytokines and their respective membrane
receptors are covered by several recent excellent reviews,
to which the reader is referred [1-4].
IL-3 is a pleiotropic cytokine, mainly produced by acti-
vated T-lymphocytes, regulating the function and pro-
duction of hematopoietic and immune cell [5]. This
cytokine was originally termed multi-colony stimulating
factor (multi-CSF) for its property to stimulate the devel-
opment of a wide-range of hematopoietic cells from bone
marrow, including basophils, neutrophils, eosinophils,* Correspondence: ugo.testa@iss.it
1Department of Hematology, Oncology and Molecular Medicine, Istituto
Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
Full list of author information is available at the end of the article
© 2014 Testa et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.macrophages, erythroid cells, megakaryocytes, and den-
dritic cells [6,7]. The biologic activity of IL-3 is not limited
only to the hematopoietic system, but it extends also to the
endothelial lineage, where IL-3 acts as a stimulator of
endothelial cell proliferation [8].
As above stated, the IL-3R is a heterodimer composed
by alpha and beta chains. The IL-3Rα chain is a glyco-
protein of 360 aminoacidic residues, composed by an
extracellular domain of 287 amino acid residues, involving
a predicted Ig-like domain, two FnIII domains, a trans-
membrane domain of 30 amino acid residues and by an
intracellular domain of 53 residues [9-12].
CD123 expression on human hematopoietic stem/
progenitor cells
Many studies have explored the expression of CD123 at
the level of repopulating stem cells and of various sub-
populations of hematopoietic progenitor cells. In this
context, CD123 expression at the level of CD34+ cells
isolated from various sources of hematopoietic cells
(fetal liver, cord blood, bone marrow and peripheral
blood) was studied. Sato an coworkers showed that a
part of human and cord blood CD34+ cells express
CD123 and the growth of these cells in the presence of
cytokines stimulating their proliferation resulted in an
increased CD123 expression [13]. Accordingly, it was
suggested that the primitive population of HPCs expressedtd. This is an Open Access article distributed under the terms of the Creative
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vided evidence that early primate HPCs identified as
CD34+/HLA-DRdull cells express low levels of CD123,
while CD34+ cells with negative or high CD123 expres-
sion were committed erythroid and myeloid progenitors,
respectively [14]. Huang and coworkers have defined
three subsets of CD34+ cells according to the level of sur-
face CD123: CD34+CD123bright cells were myeloid and
B-lymphoid progenitors, whereas the erythroid progeni-
tors were mainly contained in the CD34+CD123negative
subset; CD34+CD123low cell subset contained a hetero-
geneous population of early and committed progenitor
cells [15]. More recently, Manz and coworkers have
subfractionated the CD34+CD38+ cell population, isolated
either from bone marrow or cord blood, according to the
positivity for CD123 and CD45RA and have shown that:
IL-3RαlowCD45RA+ cells mainly contained granulo-
monocytic progenitors (GMP); IL-3Rα-CD45RA- cells
mainly contained erythroid and megakaryocytic progeni-
tors (MEP); IL-3RαlowCD45RA- cells give rise to both
GMPs and MEPs and contained the progenitors of both
populations [16].
CD123 expression during hemopoietic differentiation
was explored by Testa et al, providing evidence that this
receptor was expressed on the majority of CD34+
hemopoietic progenitors and its expression is rapidly lost
during erythroid and megakaryocytic differentiation, mod-
erately decreased during monocytic differentiation and was
sustained in the granulocytic lineage [17]. The IL-3R/GM-
CSFR/IL-5R βc was expressed at low levels in CD34
+ cells
and its expression increased during the initial stages of
granulocytic and monocytic differentiation and was main-
tained up to the late stages of maturation, while it was
transiently expressed in the erythroid and megakaryocytic
differentiation only during the early stages of differenti-
ation and then disappeared [18].
CD123 expression on normal hematopoietic stem cells
(HSCs) was addressed in some studies. Taussig and
coworkers have isolated CD34+/CD38- cells from cord
blood and bone marrow: this cell fraction contains HSCs,
defined as cells capable of long-term repopulation of
irradiated SCID mice [19]. In cord blood, the majority of
CD34+/CD38- cells expressed CD123, as well as other
myeloid antigens such as CD13 and CD33; in bone mar-
row, the percentage of CD123+ cells among CD34+/CD38-
cells was lower [19]. In a second set of experiments,
CD34+/CD38-CD123+ and CD34+/CD38- CD123- cells
were separated, providing evidence that SCID-repopulating
cells were more frequent among CD123+ than among
CD123- cells [19].
Jin and coworkers used another approach using a neu-
tralizing anti-IL-3Rα mAb (7G3); ex vivo treatment of
CD34+ bone marrow cells elicited a moderate inhibitory
effect on the SCID-repopulating capacity (a decrease ofabout 30% of the engrafting capacity was observed fol-
lowing incubation of bone marrow cells with this anti-
body). These observations indicate that only a part of
normal HSC express CD123 and therefore the majority
of them should be not affected by a therapy targeting
this receptor [20].
CD123 in blastic plasmocytoid dendritic cell neoplasm
Blastic plasmocytoid dendritic cell neoplasm (BPDCN),
formerly known as blastic natural killer cell lymphoma
CD56+/CD4+ hematodermic neoplasm, is a rare hema-
tologic malignancy derived from the uncontrolled growth
of plasmocytoid dendritic cells. The nomenclature of
BPDCN was adopted in 2008 by the World Health
Organization (WHO) classification after the analysis of
its main immunophenotypic, molecular and functional
properties, such as pronounced CD123 expression, TCL1
expression and production of type I IFN, all suggesting a
close link and a pathogenetic relation to the plasmocy-
toid dendritic cell lineage. After many years of intensive
studies various subsets of human dendritic cells have
been identified, distinguished according to their cellular
origin, phenotypic, molecular and functional properties:
(a) myeloid dendritic cells, expressing typical myeloid
antigens; (b) plasmacytoid dendritic cells (PDC), lacking
the expression of mnyeloid antigens and characterized by
the high expression of CD123; (c) CD14+ dendritic cells,
known also as interstitial dendritic cells, derived from clas-
sical monocytes; (d) Langherans and microglia cells, two
types of specialized dendritic cells, the former ones capable
of generating migratory dendritic cells and the latter ones
considered as tissue specialized macrophages. PDCs are
major type I interferon-producing cells and play an import-
ant role in antiviral immunity and induction of immuno-
logic tolerance.
The study of CD123 was of fundamental importance
for the identification and for the study of human plas-
macytoid dendritic cells. Thus, Olweus and coworkers
reported in 1997 the identification in a subset of dendritic
cells in the T cell-dependent areas of human lymphoid or-
gans of cells characterized by the high expression of
CD123; these cells are originated from CD34+/CD123high
progenitors [21]. In 2002, MacDonald and coworkers re-
ported the identification of a subset of dendritic cells in
human peripheral blood characterized by the very high
expression of CD123 [22].
In the study of BPDCN patients it was of fundamental
importance the discovery by Chaperot and coworkers
about the expression of IL-3Rα chain on CD4+/CD56+
leukemic cells: upon in vitro incubation with IL-3 the
leukemic cells undergo a partial maturation and became
a powerful inducer of naïve CD4+ T cell proliferation
[23]. In contrast, the GM-CSFRα chain (CD116) expres-
sion was absent/low on these leukemic cells [24]. Upon
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rived from BPDCN patients increased the expression of
molecules associated with antigen presentation, such as
CD1a and CD40, and displayed a consistent level of
antigen-presenting ability to allogeneic lymphocytes in
mixed lymphocyte cultures [25]. These observations in-
dicate that leukemic cells in BPDCN may act as potent
antigen cells in vivo, and this property is controlled by
IL-3 [25].
The high expression of CD123 observed on BPDCN
cells is not surprising in view of the expression of this
receptor also in the normal cellular counterpart. In fact,
immature plasmacytoid dendritic cells express IL-3Rα.
Importantly, IL-3 is required for an efficient in vitro
generation of plasmacytoid dendritic cells [26]. Thus,
Buelens and coworkers showed that monocytes cul-
tured with IL-3 and IFN-beta give rise to a popula-
tion of dendritic cells displaying many properties of
plasmacytoid DCs and highly expressing CD123. A more
recent study provided evidence that IL-3 cooperates
with FLT3 Ligand and TPO to induce the efficient
production of plasmacytoid dendritic cells displaying
phenotypic and functional properties of plasmacytoid
dendritic cells [27].
Patients with BPDCN have a poor prognosis when
treated with conventional standard chemotherapy. The
only treatment capable of inducing durable remissions is
the high-dose therapy followed by allogeneic-stem cell
transplantation (allo-SCT); in this setting, graft-versus-
malignancy effects can contribute to BPDCN control
after allo-SCT [28]. In a recent study representing the
largest series of these patients (43 patients) never re-
ported in the literature, it was observed a median overall
survival of about 8-9 months following treatment with
standard chemotherapeutic regimens used for AMLs
and ALLs; the median overall survival of patients under-
going allogeneic stem cell transplantation was about
23 months [29].
Given the high IL-3Rα expression observed on
CD4+CD56+ leukemic cells and their poor response to
standard therapy it seemed important to evaluate a pos-
sible therapeutic approach through the targeting of this
membrane receptor. Thus, Frankel and coworkers have re-
cently reported the treatment of seven BPDCN patients
(some heavily pretreated) with SL-401, an agent targeting
the IL-3Rα (this agent is composed by human IL-3 coupled
to a truncated diphtheria toxin payload). A single cycle of
5-days treatment with this agent at 12.5mcg/kg IV over
15 minutes elicited a pronounced anti-tumor response in-
ducing clinical remissions in most patients lasting several
months to over a year [30]. These preliminary promising
observations represent the basis for future studies involving
multiple cycles of treatment and the enrolling in the future
of less heavily treated patients.CD123 in hairy cell leukemia
CD123 expression was explored in B lymphoproliferative
disorders of mature B-lymphocytes. An initial study was
based on the analysis of 122 patients with lymphoprolif-
erative disorders of mature B-lymphocytes, showing that
the large majority of chronic lymphocytic leukemias and
mantle and follicular lymphomas were CD123 negative,
while CD123 was constantly expressed on hairy cell
leukemia cells [31]. Del Giudice and coworkers have ex-
plored in detail the expression of CD123 in neoplastic
cells derived from 59 patients with B-cell disorders with
circulating hairy or villous lymphocytes: CD123 was
expressed on hairy cell leukemia, but not on the variant
form of hairy cell leukemia and splenic lymphoma with
villous lymphocytes [32]. A more recent study confirmed
the importance of CD123 to differentiate hairy cell
leukemia from hairy cell leukemia-variant: in fact, while
HCLs strongly express CD123, the expression of this
membrane receptor was absent or low/very low on
HCL-variant cells [33]. Other criteria help to distinguish
these two similar diseases, such as the morphology,
the positivity for annexin A1 and the presence of the
BRAFV600E mutation [33]. Another recent study showed
that the positivity for CD123 was essential for distinguish-
ing both HCL and HCL-variants from other B-cell chronic
lymphoproliferative disorders; furthermore, the positivity
for CD123 was essential for distinguishing HCL from
HCL-variant [34].
CD123 in acute lymphocytic leukemias
An initial study by Munoz and coworkers, based on the
analysis of a small number of patients, provided evidence
that B-ALL express CD123, while T-ALLs were CD123-
negative [31]. Importantly, in this study these authors have
explored also normal bone marrow CD19+CD33-CD10+
B-lymphoid precursors and have observed that these
cells are CD123-negative [31]. Testa and coworkers have
confirmed these observations [35].
In 2009, Djokic and coworkers reported a detailed ana-
lysis of CD123 expression on B-ALLs. Particularly, these
authors analyzed 95 pediatric and 24 adult B-ALLs,
showing that in 31% of cases B-ALL blasts displayed
strong CD123 expression, in 61% moderate expression
and in 8% of cases were CD123-negative [28]. In con-
trast, early B-cell precursors, intermediate B-cells and
mature B-lymphocytes displayed only absent or low
CD123 expression [36]. The correlation between CD123
expression and molecular B-ALL subtypes showed several
interesting findings: the CD123 expression in B-ALLs cor-
related with hyperploid genotype, a frequent genetic abnor-
mality in childhood ALLs; in contrast, B-ALLs associated
with other genetic abnormalities, such as ETV6/RUNX1,
BCR/ABL1, PBX1/TGF3 translocations or a normal karyo-
type, did not display CD123 overexpression, compared to
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have confirmed these findings and, particularly, have ana-
lyzed the normal compartment of B-cell precursors, as well
as B-ALL leukemic blasts [37]. Particularly, these authors
have shown that early B-cell CD3+ precursors do not ex-
press CD123, while more mature CD34+ B-cell elements
display the CD123 expression. In B-ALLs in 89% of cases
CD123 expression was observed: in 80% of cases CD123
expression was associated with CD34 expression; in 9% of
cases ALL blasts express CD123, but not CD34 [37]. Ac-
cording to these observations, these authors concluded
that while in normal B cell precursors a discordant pattern
of CD123 and CD34 antigen expression was observed, in
B-ALL blasts a concordant pattern of expression of these
two antigens was observed [37]. Interestingly, in the major-
ity of B-ALL patients, CD123+/CD34+ cells were observed
post-chemotherapy [37]. In a more recent study Coustan-
Smith and coworkers carried out an analysis on 270 pa-
tients with newly diagnosed childhood ALL based on the
analysis by flow cytometry of 30 membrane antigens, in-
cluding CD123 [38]. Of these 30 markers, 22 were differen-
tially expressed in ALL cases compared to CD19+CD10+
B-cell progenitors; particularly, CD123 was markedly more
expressed in the majority of cases on B-ALL blasts, com-
pared to normal B cell progenitors [38]. Some of these
markers, including CD123 were shown to be very useful fo
the detection of minimal residual disease, even at the level
of the definition of a very minor residual lymphoid
leukemic cell population [38]. It is important to underline
that this study based on the analysis of a large number of
B-ALL samples allowed also to define the ALL genetic
subtypes exhibiting the highest CD123 expression. This
analysis unequivocally allowed to establish that hyperdi-
ploid B-ALLs (51-65 chromosomes) highly expressed
CD123 [38]. CD123, together with CD86, CD97 and
CD200 (all overexpressed) may be used for a tentative
flow cytometric identification of hyperdiploid B-ALLs
[38]. The very pronounced CD123 expression in hyperdi-
ploid B-ALLs offers the opportunity for a possible thera-
peutic targeting [38].
CD123 in Acute Myeloblastic Leukemia (AML)
CD123 expression in AML was explored in detail and
these studies have recently led to the therapeutic target-
ing of this receptor. Initial studies in AMLs have defined
an aberrant overexpression of CD123 on CD34+CD38-
AML cells, while the normal bone marrow counterpart
CD34+CD38- does not express CD123 [39]. To assess
the functional role of CD34+CD38-CD123+ cells these
cells were purified from AML samples and injected into
immunodeficient mice: these cells were able to initiate
and maintain the leukemic process into immunodefi-
cient mice and, therefore, act as leukemic stem cells
[39]. In a subsequent study Munoz and coworkers haveperformed a screening on IL-3Rα expression in hemo-
lymphopoietic malignancies provided evidence that this
membrane receptor is very frequently expressed in B-ALL
and AML [31].
Given these initial observations, Testa and coworkers
have explored a large number of AMLs and ALLs with
the particular aim of defining a possible overexpression
of this membrane receptor compared to the normal
counterpart (i.e., normal CD34+ cells), showing that IL-3Rα
was overexpressed in 45% of AML patients [35].
Subsequent studies on IL-3Rα in AMLs have been per-
formed with the specific aim of defining the possible
biologic effects induced by IL-3Rα overexpression in
leukemic blasts, the AML subsets particularly associated
with the receptor hyperexpression and the receptor ex-
pression on leukemic stem cells.
Testa and coworkers have explored the possible ef-
fects induced by CD123 overexpression at the level
of leukemic cells and have shown that: (a) leukemic blasts
overexpressing IL-3Rα exhibit higher cycling activity and
increased resistance to apoptotic triggering elicited by
growth factor deprivation; (b) AMLs overexpressing IL-3Rα
frequently display constitutive Stat5 phosphorylation; (c)
the incubation of AML blasts displaying high IL-3Rα ex-
pression with IL-3 induced Stat5 activation at significantly
higher levels than in leukemic cells with normal IL-3Rα
levels [35]. Importantly, IL-3Rα overexpression on AML
blasts was associated with increased cellularity at diagnosis
and with a negative prognosis [35].
Other studies were focused to the identification of
AML subsets associated with IL-3Rα overexpression. In
this context, initial observations by Testa and coworkers
showed AMLs expressing high levels of CD123 displayed
some peculiar immunophenotypical features [40]. Sub-
sequent studies have shown that AMLs overexpressing
IL-3Rα are frequently associated with AMLs displaying
FLT3-Internal Tandem Duplication (FLT3-ITD) muta-
tions and are associated with some frequent immuno-
phenotypical features consisting in low CD34 expression
and high CD11b and CD14 expression [41]. Importantly,
in these AMLs the high CD123 expression well corre-
lated with CDw131 (IL-3R βc) and CD116 (GM-CSFRα)
expression, thus suggesting in these AMLs the con-
comitant overexpression of functional IL-3R and GM-
CSFR. These AMLs were also characterized by the
co-expression of receptors for endothelial growth factor
[41]. Interestingly, high IL-3Rα levels were also observed
in a subgroup of AML patients characterized by FLT3
overexpression, not associated with mutations of this
receptor [42]. According to these two studies it was sug-
gested that in the majority of AMLs overexpressing
CD123 the enhanced and deregulated signaling origi-
nated by IL-3R and FLT3 contribute to provide a survival
and growth advantage to leukemic AML blasts [42]. These
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Rollins-Raval have shown that CD123 overexpression was
observed in 83% of FLT3-ITD-mutated AMLs [43]. Fur-
thermore, 62% of AML cases with nucleophosmin muta-
tions displayed CD123 overexpression [43]. Gonen and
coworkers have identified a subgroup of AMLs, pertaining
to the cytogenetically intermediate-risk group, character-
ized by CD25 (IL-2R) positivity and by a poor prognosis:
these AMLs display CD123 overexpression and frequently
have FLT3-ITD mutations [44].
Many studies were devoted to the analysis of IL-3Rα
expression in leukemic stem cells (LSCs). As above men-
tioned, an initial study by Jordan and coworkers pro-
vided evidence that CD34+/CD38- purified leukemic
cells, enriched in LSCs, overexpress in the majority of
AMLs CD123. CD123+/CD34+ leukemic cells were able
to initiate a leukemic process when transplanted into
immunodeficient mice [45]. The CD123 was then used
in other studies as a marker to isolate LSC populations
from AML samples and to provide a characterization of
these cells and it was shown that these cells display a con-
stitutive activation of NF-kB [45]. Putative CD34+/CD38-/
CD123+ LSCs were detectable in about 75% of AMLs [46]
and their number is predictive of the clinical outcome [47].
In fact, a proportion of CD34+/CD38-/CD123+ cells greater
than 15% in AML patients with unfavourable karyotype
was associated with a lack of complete remission; further-
more, the presence of more than 1% of CD34+/CD38-/
CD123+ cells had a negative impact on disease-free survival
and overall survival [47].
Other recent studies have provided evidence that
CD123 is a useful marker of leukemia-initiating cells in
Fanconi anemia AML cells. In fact, Du and coworkers
have isolated CD34+/CD38- cells from three Fanconi
anemia patients: Starting from these cells IL-3Rα+ and
IL-3Rα- subpopulations and only the positive population
was able to initiate the development of a leukemic process
when inoculated into immunodeficient mice [48].
The definition of treatment response criteria is of fun-
damental importance for the development of more effi-
cacious therapeutic strategies for AMLs, but these
criteria remained virtually unchanged and the definition
of “complete remission” remained still basically the same
of many years ago [49]. In spite these limitations, several
clinical trials have shown that high-sensitivity meas-
urement of residual disease burden (minimal residual
disease, MRD) during and after treatment can be per-
formed and may be used to try to improve clinical out-
comes by guiding to additional clinical interventions of
some patients in complete clinical remission [49]. The
measument of MRD represents already the standard of
care for CML and APL, but it could be extended also to
non-APL AMLs. The evaluation of MRD on these AMLs
is mainly related to the detection of leukemia-specificgenetic abnormalities. However, the analysis of MRD in
AML patients could be also performed through the moni-
toring by flow cytometry of leukemic cell populations.
Recent studies suggest that the levels of expression of
CD123 and of other membrane antigens represent a
strong prognostic marker for relapse. Recent studies car-
ried out by Larsen and coworkers have identified the hu-
man Myeloid Inhibitory C type-like lectin (hMICL) as a
stable and reliable AML antigen expressed in 90% of AML
samples, as well as CD123 [50]; importantly, the expres-
sion of these two antigens remained constant in paired
samples at diagnosis and at relapse [50]. In a second study
the same authors provided evidence that the detection
of these two membrane markers could represent a
very useful tool as a Minimal Residual Disease (MRD)
prognostic biomarker. The detection of high levels of
CD123+/hMCL+ cells at post-induction time-point repre-
sent a strong prognostic marker for relapse in patients in
hematological complete response [51]. Importantly, in
post-induction AML patients CD123+/hMCL+ levels
strongly correlate with the level of suitable molecular
markers detected by qPCR [43]. Other recent studies
have addressed the potential utility of the detection of
CD123+/hMCL+ cells for the monitoring and for the
study of MRD in FLT3-ITD+ AML patients. A first study
clearly showed that the existence of high FLT3-ITD al-
lelic burdens in CD123+/hMCL+ FLT3-ITD+ AML blasts
at diagnosis, thus indicating that these cells are malignant
[52]. A second study provided evidence that CD123 ex-
pression predicts minimal residual disease and relapse in
AML patients with FLT3-ITD mutations [53]. CD123 ex-
pression in FLT3-ITD+ AMLs at the level of a cell popu-
lation CD34+CD38-CD99+ enriched in leukemic stem
cels was clearly higher that detectable on the same cell
population isolated from normal bone marrow; interest-
ingly, these CD123+ leukemic cells exhibited an increased
level of cell signaling activity along the Stat5 and PI3K/
AKT pathways [53].
Targeting of IL-3R in acute leukemias
All these findings have suggested that IL-3R may repre-
sent a potentially important target for the development
of new antileukemic drugs [40]. Since the IL-3R is a
membrane receptor there are three means to target this
molecule, either using its natural ligand or specific mono-
clonal antibodies or a small molecule inhibiting the recep-
tor signaling.
In this context, initial studies were focused to develop
a IL-3R targeting agent besed on the natural ligand IL-3.
To this end, a genetically engineered fusion toxin com-
posed of the first 388 amino acid residues of diphteria
toxin (DT) with a His-Met (H-M) linker was fused to
human IL-3 [54]. This DT388IL-3 was shown to be toxic
for leukemic blasts [55] and in vivo studies have shown
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antly, the rate of cell killing of leukemic blasts induced
by DT388IL-3 was significantly correlated with the level
of IL-3Rα/IL-3Rβ expressed on leukemic blasts [57-59].
It is important to note that the DT388IL-3 fusion protein
was found to be toxic toward leukemia-initiating cells
[58]. Interestingly, the fusion of the DT to a variant of
IL-3 with increased binding affinity (IL-3[K116W]) resulted
in a fusion protein, DT388IL-3[K116W] significantly more
active than DT388IL-3 in mediating leukemic cell killing
[55]. Interestingly, DT388IL-3[K116W] was clearly more ac-
tive than DT388IL-3 in mediating the killing of leukemic
progenitor cells [59].
A second approach to target the IL-3R in leukemic
cells is represented by the use of a specific monoclonal
antibody. In this context, a neutralizing anti-IL-3R could
be a perfect reagent for its properties to neutralize IL-3R
from one side and to activate innate immunity from the
other side. A reagent corresponding to these properties
is represented by the anti-CD123 mAb 7G3 capable of
inhibiting IL-3-mediated proliferation of leukemic cell
lines [60]. It was shown that the targeting of CD123
using the 7G3 mAb impairs leukemic stem cells in vivo
[20]. This effect seems to be related to two different
mechanisms: one dependent upon inhibition of homing
and engraftment of leukemic CD34+/CD38- cells into
immunodeficient mice; the other related to the activa-
tion of innate immunity into NOD/SCID mice [20]. It is
important to note that the inhibitory effects of the 7G3
mAb are not restricted only to the CD34+/CD38- leukemic
subpopulation, but are exerted on the whole bulk leukemic
cell population [20].
Using the 7G3 mAb a construct was developed linking
to this antibody a nuclear traslocation sequence (NLS)
and (111)In [(111)In-NLS-7G3] [61]. This modified mAb
was able to bind to AML cells, to be internalized and to be
imported into the nucleus [61]. Using AMl cells labeled
with this modified antibody it was possible to determine
the sites of engraftment of leukemic cells into immunodefi-
cient mice [61].
The 7G3 monoclonal antibody was humanised and
affinity-matured and it was engineered at the level of the
Fc-domain to optimise potential cytotoxicity against
AML cells: the resultant antibody, CSL362, retained the
ability to neutralise IL-3 and exhibited enhnaced affinity
for the FcgammaRIIIa (CD16) on NK cells [62]. In vitro
and in vivo studies supported a greater activity of CSL362,
compared to the native 7G3 mAb, against CD123+
leukemic cells [60]. Both whole leukemic AML blasts and
CD34+CD38-CD123+ leukemic stem cells were sensitive to
CSL362-induced ADCC [62]. The isolation of this antibody
prompted its preclinical exploration in view of future clin-
ical studies. Pre-clinical studies to evaluate the pharmaco-
kinetic and pharmacodynamic properties of CSL362 havebeen carried out in non-human primates [63]. These
studies provided evidence for that it concerns pharmaco-
kinetics about a pharmacokinetic profile similar to that
previously reported for other humanised antibodies and
for that concerns pharmacodynamics about a marked
dose-dependent depletion of peripheral blood basophils
and plasmacellular dendritic cells, associated with a
transient decrease of NK lymphocytes and with virtually
no effects at the level of monocytes and pluripotent
bone marrow progenitor/stem cells [63]. These pharma-
codynamic studies were completed by the observation
that CSL362 administration to NSG mice xenografted
with human primary AML cells considerably potentiated
the antileukemic effect elicited by the administration
of the drug combination cytabarine/daunorubicin [64].
Interestingly, a recent study provided evidence that the
CSL362 antibody seems to be able to induce the killing of
leukemic stem cells in chronic myeloid leukemia (CML).
In fact, Nievergall and coworkers have shown that CD123
is overexpressed in CD34+CD38- CML cells, compared to
normal CD34+CD38- cells: these levels of CD123 expres-
sion were higher both in chroinic phase and blast crisis
CML patients, with levels increasing upon disease progres-
sion [65]. CSL362 was able to target and to kill CD123+
CML leukemic stem cells and markedly reduced engraft-
ment of CML cells into NSG mice [65]. It is of interest to
note that in mice treated with CSL362 ADCC-facilitated
lysis of CD123+ leukemic cells was mediated not by mouse
NK cells, but also by the few CML patients’ autologous NK
cells [65]. Importantly, CSL362 neutralized IL-3-mediated
rescue of tyrosine kinase inhibitor (TKI)-induced cell death
and potentiated the effect of TKIs at the level of CML pro-
genitors [65].
Recently, Kuo and coworkers have reported the devel-
opment of a bifunctional fusion anti-CD123 and anti-
CD3 antibody (CD123xCD3 bispecific scFv). This fusion
antibody exhibits several interesting properties: (a) it
exhibits increased target cell-binding affinity; (b) it pos-
sesses increased stability due to increased serum half-
life; (c) it is able to achieve T-cell-mediated target cell
killing [66]. More recently, Hussaini and coworkers have
reported the development of a bispecific antibody, con-
taining VH of one antibody in tandem with the VL of the
other antibody and interacting with the N-terminal
extracellular domain of human CD123 and to the extra-
cellular domain of CD3 in the human T cell receptor
complex [67]. The incubation of this CD3xCD123 DART
with leukemic AML blasts resulted in a marked activa-
tion and proliferation of T cells present in these cells and
in the killing of leukemic cells [67]. The infusion of
DARTs to AML xenografts into NSG mice resulted in an
almost complete clearance of leukemic cells in peripheral
blood and in subtotal inhibition of leukemic cells in bone
marrow [67].
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novel conjugate of single-chain Fv antibody fragments
specific for CD123 with an anti-CD16 antibody. This fu-
sion antibody exerts a potent lysis of leukemic cells [68].
Through the anti-CD16 moiety this fusion antibody is
able to bind NK lymphocytes and monocytes/macro-
phages [68]. The same authors reported the construction
of a recombinant trispecific single-chain Fv derivative
directed against CD123, CD33 and CD16, mediated ef-
fective elimination of AML cells, including leukemic
stem cells [69].
Finally, Tettamanti and coworkers have reported a dif-
ferent approach for targeting CD123 based on the trans-
duction of cytokine-induced killer (CIK) cells with a
retroviral vector encoding an anti-CD123 chimeric anti-
gen receptor [70]. Transduced CIK cells were able to kill
AML blast cells, including leukemic stem/progenitor cell
populations [70]. Another recent study reported the de-
velopment of two Chimeric Antigen Receptors (CARs)
containing a CD123 specific ScFv in combination with a
CD28 costimulatory domain and CD3-related signaling
domain, targeting different epitopes of CD123 [71].
CD123 CAR redirected cytotoxic T cells exerted potent
effector activity in vitro and in vivo against CD123+
AML cells [71]. Importantly, T cells derived from AML
patients were modified to express CD123 CARs and
were shown to be able to lyse autologous AML blasts
in vivo [71]. Furthermore, Gill and coworkers reported
the development of a CAR consisting a CD123-specific
ScFv-derived from hybridoma clone 32716 and signaling
domains from 4-1BB (CD137) and TCR-ζ [72]. CART
cells incubated in the presence of primary AML blasts
undergo proliferation, release of inflammatory cytokines
and induced the killing of leukemic cells; in NOD-SCID-
IL2Rγ-/- (NSG) mice engrafted with either leukemic cell
lines or primary leukemic blasts, CART 123 treatment
induced the eradication or a marked inhibtion of leukemic
growth, respectively; CART 123 immunotherapy of NSG
mice reconstituted with normal human CD34+ cells re-
sulted in a non-complete eradication of human bone
marow cells [72]. These observations have suggested that
CART 123 could represent a novel valuable conditioning
regimen prior to hematopoietic cell transplantation [72].
Some of these compounds entered phase I clinical
studies (Table 1) aiming to define the safety profile and
to have the first indications about a possible therapeutic
impact of CD123 targeting in patients with advancer
AMLs. Thus, the fusion molecule composed by human
IL-3 fused to a truncated diphteria toxin payload (the
compound was called SL-401) was introduced in a phase I
clinical trial aiming to evaluate its safety and therapeutical
impact in a group of AML patients heavily pretreated [73].
In this study, SL-401 demonstrated the induction of ob-
jective clinical responses, including 2 durable completeresponses and 5 partial responses and improved the over-
all survival [73]. Furthermore, the SL-401 administration
was well tolerated [73]. The same compound SL-401 was
evaluated also in the context of a phase I clinical study
involving eight patients with blastic plasmocytoid den-
dritic cell neoplasms [30]. In this group of heavily pre-
treated patients with advanced disease the treatment
with a single cycle of SL-401 was well tolerated and dem-
onstrated prominent antitumor activity, with most of
patients achieving a complete response [30].
Other phase I studies involved the use of monoclonal
antibodies anti-CD123. CSL360 is a recombinant chimeric
mAb that binds to IL-3Rα at the level of the same epitope
recognized by the 7G3 mAb. 40 patients with relapsed, re-
fractory or high-risk AML were treated with intravenous
infusions of this antibody ranging from 0.1 to 10 mg/kg.
The patients did not show any significant response to
the treatment, with exception of one patient achieving a
complete response [74]. Another phase I study of CSL362
(anti-IL-3Rα/CD123 monoclonal antibody) in patients with
CD123+ acute myeloid leukemia in complete remission or
complete remission with incomplete platelet recovery at
high risk for early relapse is ongoing (NCT01632852,
Clinical Trials Gov).
In the next decade, advances in patient selection and
drug design should establish a role for CD123 targeted
therapy in hematologic malignancies.
Conclusions and future directions
In conclusion, the strudies carried out during the last
two decades have clearly shown that CD123 is overex-
pressed in many hematologic malignancies, including
BPDCNs, AMLs, B-ALLs, Hairy Cell Leukemia. Import-
antly, in some of these conditions, such as AMLs, the
high expression of CD123 is a feature of leukemic stem
cells, making very attractive the opportunity to thera-
peutically target this membrane receptor. Therefore,
various agents have been developed in an attempt to use
CD123 targeting to kill leukemic cells overexpressing
this receptor, either using a fusion protein formed by re-
combinant IL3 fused to diphteria toxin (SL401) or a hu-
manized neutralizing anti-CD123 monoclonal antibody
or T cells transduced withg a retroviral vector encoding
an anti-CD123 chimeric antigen receptor. Some of these
compounds were introduced in clinical studies in the
context of phase I studies in AML and BPDCN patients
with promising results. Additional studies will be re-
quired to assess the role of these CD123-targeting drugs,
not only when used alone, but also in combination with
standard anti-leukemic drugs in the treatment of various
leukemic cionditions. Furthermore, it would be particu-
larly interesting to assess the possible therapeutic impact
of CD123-targeting drugs to attempt the treatment of
minimal residual disease.
Table 1 Agents used for the targeting of CD123 in leukemic patients





Induces a pronounced clearing
of leukemic cells, including AML
blasts, BPDCN tumor cells, MM cells
Induces killing of CFU-L. Induces the
killing of CD34+/CD38- leukemic cells
40-50% inhibition of CFU-GM Induces the apoptotic killing of
cells expressing CD123
Phase I in AMLs and
BPDCN. Phase II studies
are planned
CSL362 (humanized form
of the 7G3 anti-CD123
mAb, IL3 neutralizing)
Reduces AML leukemic stem cell
homing, engraftment and
self-renewal ability and improves
the survival of mice, with minimal
effect on normal BM cells
Inhibits spontaneous and IL3-induced
proliferation of CD34+/CD38- leukemic
cells. In vivo treatment of xenografted
NOD/SCID mice targets LSCs
Dose-dependent depletion of PB
basophils and plasmacellular
dendritic cells, transient decrease
of NK cells and no effect on
monocytes and HPCs and HSCs.
ADCC-facilitated lysis of leukemic
CD123+ leukemic cells mediated
by NK cells
Phase I in AMLs
CD123 CART cells (T cells
expressing CD123-specific
receptors)
Induces an antileukemic effect in
nude mice xenografted with
human CD123+ AML cells
70-80% inhibition of CFU-L 40-50% inhibition of CFU-GM;
10-20% inhibition of BFU-E. The
cytotoxic effect is limited to
cells displaying high CD123
expression
Antibody-mediated T cell killing
of CD123+ leukemic cells. Activation
of cytokine production and effector
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